After joining the study, you will be assigned to one of the treatment groups. The assignment will be done randomly, which means neither you nor your doctor can choose which group you will be in.

You may receive either camizestrant (a new type of medicine that blocks estrogen receptors) or standard endocrine therapy (which includes medicines called aromatase inhibitors or tamoxifen). Some patients may also receive an additional medicine called abemaciclib.

The treatment will depend on which group you are assigned to. All medicines in this study are taken by mouth as tablets, except for some hormone-suppressing medicines which may be given as injections into the muscle or under the skin.

If you receive camizestrant, you will take it orally as a tablet. The exact dosage and frequency will be determined by the study protocol.

If you receive standard endocrine therapy, you may take one of the following medicines orally: anastrozole (such as Arimidex 1 mg tablet), letrozole, exemestane, or tamoxifen citrate (such as Nolvadex 20 mg tablet). These medicines work by either blocking estrogen production or blocking estrogen from affecting breast cancer cells.

Some patients may also need to take medicines that suppress hormone production from the ovaries. These include triptorelin, leuprorelin acetate, or goserelin, which are given as injections into the muscle or under the skin.

If you are assigned to receive abemaciclib in addition to the main treatment, you will take it orally as a tablet.

The treatment period is expected to last for several years, as this is an adjuvant therapy designed to prevent cancer from returning after your initial treatment.

Throughout the study, you will have regular visits to monitor your health and the effects of the treatment.

During these visits, blood samples will be taken to check your organ function and blood cell counts, and to measure the levels of the study medicine in your blood.

Your vital signs, such as blood pressure and heart rate, will be measured at each visit.

You will be asked about any side effects or health problems you have experienced since your last visit.

At certain times during the study, you will be asked to complete questionnaires about your quality of life and any side effects you are experiencing.

These questionnaires will ask about your physical well-being, emotional state, and how the treatment is affecting your daily activities.

The information you provide will help assess how the treatment impacts your overall well-being.

The study will continue for many years to monitor whether the breast cancer returns and to track your overall health.

You will continue to have regular follow-up visits even after you complete the active treatment phase.

The study is expected to continue until 2037, although your individual participation may vary depending on your response to treatment and overall health.

Throughout your participation, it is important to report any new symptoms, health problems, or side effects to your study doctor.

Any serious health events will be carefully documented and assessed to ensure your safety during the study.